Adaptive radiotherapy: Strategies and benefits depending on tumor localization.

[Adaptive radiotherapy: Strategies and benefits depending on tumor localization]. Cancer Radiother. 2019 Aug 16;: Authors: Briens A, Castelli J, Barateau A, Jaksic N, Gnep K, Simon A, De Crevoisier R Abstract Adaptive radiotherapy (ART) is a complexe image-guided radiotherapy modality that comprises multiple planning to account for anatomical variations occurring during irradiation. Schematically, two strategies of RTA can be distinguished and combined according to tumor locations. One or more replanning can be proposed to correct systematic variations such as tumor shrinkage. A library of treatment plans with day-to-day plan selection from cone-beam CT imaging can also be proposed to correct random variations such as uterine motion or bladder/rectum volume changes. Because of strong anatomical variations occurring during irradiation, RTA appears therefore particularly justified in head and neck, lung, bladder, cervical and rectum and pancreas tumors, and to a lesser extent for prostate tumors and other digestive tumors. For these tumor locations, ART provides a fairly clear dosimetric benefit but a clinical benefit not yet formally demonstrated. ART cannot be proposed in a routine practice but must be evaluated medico-economically in the context of prospective trials. A rigorous quality control must be associated. PMID: 31427077 [PubMed - as supplied by publisher]
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research

Related Links:

CONCLUSION: Structural prevention measures in addition to behavioral measures enable a reduction of the cancer risk caused by UV radiation. The aim must be to establish these measures nationwide for the entire population. PMID: 32494842 [PubMed - as supplied by publisher]
Source: Der Hautarzt: Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - Category: Dermatology Tags: Hautarzt Source Type: research
This study sought to determine the incidence rates of all gynecologic, including peritoneal, malignancies in the U.S. Active Duty population compared to the general US population as reported in the Surveillance, Epidemiology, and End Results Program database. MATERIALS AND METHODS: Gynecologic cancers diagnosed in U.S. Active Duty women aged 20-59 between 2004 and 2013 were retrospectively ascertained. Cancer cases were identified in both the Automated Central Tumor Registry and the Military Health System Data Repository. All cases in Automated Central Tumor Registry plus cases recorded in Military Health System Data R...
Source: Military Medicine - Category: International Medicine & Public Health Tags: Mil Med Source Type: research
Publication date: Available online 5 June 2020Source: Gynecologic Oncology ReportsAuthor(s): Maryam Kasraeian, Kamran Hessami, Homeira Vafaei, Nasrin Asadi, Leila Foroughinia, Shohreh Roozmeh, Khadije Bazrfashan
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Publication date: Available online 4 June 2020Source: Gynecologic Oncology ReportsAuthor(s): María Jesús Rubio, María José Lecumberri, Silvia Varela, Jesús Alarcón, María Eugenia Ortega, Lydia Gaba, Jaime Espinós, Julia Calzas, Pilar Barretina, Isabel Ruiz, Gloria Marquina, Ana Santaballa
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Mutations in Tumor Protein P53 (p53) are expressed in a variety of human cancers such as cholangiocarcinoma, melanoma, colon cancer, rectal cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer (NSCLC), glioblastoma, uterine cervical cancer, head and neck cancer, breast cancer, pancreatic cancer, and bladder cancer. The p53 protein is involved in determining whether DNA is repaired or the damaged cell undergoes apoptosis – thus acting as a tumor suppressor by regulating cell division. Mutations in the p53 protein can reduce or eliminate its tumor suppressor function or interfere with wild type p53 in...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
Publication date: Available online 16 June 2016 Source:Regulatory Toxicology and Pharmacology Author(s): Peter N. Lee, Alison J. Thornton, Janette S. Hamling We reviewed 87 epidemiological studies relating environmental tobacco smoke (ETS) exposure to risk of cancer other than lung or breast in never smoking adults. This updates a 2002 review which also considered breast cancer. Meta-analysis showed no significant relationship with ETS for nasopharynx cancer, head and neck cancer, various digestive cancers (stomach, rectum, colorectal, liver, pancreas), or cancers of endometrium, ovary, bladder and brain. For some can...
Source: Regulatory Toxicology and Pharmacology - Category: Toxicology Source Type: research
Abstract We reviewed 87 epidemiological studies relating environmental tobacco smoke (ETS) exposure to risk of cancer other than lung or breast in never smoking adults. This updates a 2002 review which also considered breast cancer. Meta-analysis showed no significant relationship with ETS for nasopharynx cancer, head and neck cancer, various digestive cancers (stomach, rectum, colorectal, liver, pancreas), or cancers of endometrium, ovary, bladder and brain. For some cancers (including oesophagus, colon, gall bladder and lymphoma) more limited data did not suggest a relationship. An increased cervix cancer risk (...
Source: Regulatory Toxicology and Pharmacology : RTP - Category: Toxicology Authors: Tags: Regul Toxicol Pharmacol Source Type: research
Abstract High expression of cell division cycle 20 homolog (CDC20), a key component of the spindle assembly checkpoint (SAC), has been reported in various malignancies and plays a vital role in tumorigenesis and progression. The goal of this study was to evaluate the utility of CDC20 immunostaining in a wide range of malignant tumors. CDC20 immunohistochemistry was evaluated in normal tissues and compared to the most frequently occurring malignant tumors in these tissues (bladder, breast, cervical, colonic, endometrial, gastric, head and neck, liver, lung, ovarian, pancreatic, prostatic, renal, thyroid carcinomas,...
Source: Tumor Biology - Category: Cancer & Oncology Source Type: research
On May 20, 2015, New York State will host its Cancer Prevention Summit in Manhattan. This bold initiative is the work of the New York State Commissioner of Health, Dr. Howard Zucker, and his colleagues at the New York State Department of Health. Many health related organizations in New York are participating in the Summit, and the audience will be challenged with action points. I am honored to participate in the Cancer Prevention Summit as a speaker, and will introduce the keynote speaker, Dr. Graham Colditz, an internationally recognized leader in the prevention of cancer and other diseases. The Summit's focus is the p...
Source: Science - The Huffington Post - Category: Science Source Type: news
This study examines historical trends in adjuvant and neoadjuvant radiation therapy (ANRT) before or after cancer-directed surgery to identify disease sites that may benefit from coordinated care. Methods: The Surveillance, Epidemiology, and End Results database was queried to identify patients with bladder cancer; breast cancer; cervical cancer; colorectal cancer; kidney cancer; cancer of the lung, bronchus, and pleura; lymphoma; melanoma; cancer of the oral cavity and pharynx; ovarian cancer; pancreatic cancer; prostate cancer; thyroid cancer; and uterine cancer from 1973 to 2011. Number and percentage of patients who re...
Source: The Cancer Journal - Category: Cancer & Oncology Tags: Original Articles Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Cancer of the Uterus | Cervical Cancer | Colorectal Cancer | Databases & Libraries | Head and Neck Cancer | Pancreas | Pancreatic Cancer